Akari Therapeutics PLC logo

Akari Therapeutics PLC - ADR

NAS:AKTX (USA)   ADR
$ 1.19 -0.005 (-0.42%) 08:08 PM EST
Volume:
10.00K
Avg Vol (2M):
14.85K
Also Trade In:
Volume:
10.00K
Avg Vol (2M):
14.85K

Business Description

Akari Therapeutics PLC logo
Akari Therapeutics PLC
NAICS : 325412 SIC : 2834
ISIN : US00972G1085

Share Class Description:

AKTX: ADR
Description
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset -0.05
Debt-to-EBITDA N/A
N/A
N/A
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 32.9
3-Year EPS without NRI Growth Rate 45
3-Year FCF Growth Rate 32.1
Name Current Vs Industry Vs History
5-Day RSI 42.82
9-Day RSI 34.18
14-Day RSI 30.65
6-1 Month Momentum % -47.23
12-1 Month Momentum % -49.23

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.95
Quick Ratio 0.95
Cash Ratio 0.84

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -51
Name Current Vs Industry Vs History

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio N/A
N/A
N/A
PE Ratio without NRI N/A
N/A
N/A
EV-to-EBIT -0.33
EV-to-EBITDA -0.33
EV-to-FCF -0.34
Earnings Yield (Greenblatt) % -303.03
FCF Yield % -175.05